Trials / Terminated
TerminatedNCT02041091
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 226 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tabalumab Auto-Injector | Administered SC |
| DRUG | Tabalumab Prefilled Syringe | Administered SC |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2015-11-01
- First posted
- 2014-01-20
- Last updated
- 2018-06-15
- Results posted
- 2018-06-15
Locations
44 sites across 3 countries: United States, Puerto Rico, South Korea
Source: ClinicalTrials.gov record NCT02041091. Inclusion in this directory is not an endorsement.